-
General
Polyneuron and University of Basel awarded grant of CHF 1.2 M to advance novel treatments to support ABO-Incompatible transplantsPolyneuron is proud to announce that – together with the University of Basel – we awarded grant of CHF 1.2M to advance novel treatments to support ABO-Incompatible transplants. Press Release… [read on]
-
General
Polyneuron extends Series A to CHF 36.5 millionPolyneuron announces a CHF 14 million extension of the Series A, bringing the total to CHF 36.5 million. HBM Healthcare Investments has joined the consortium of investors in the Series A, led by Sofinnova Partners, and which included New Enterprise Associates (NEA) and other private… [read on]
-
General
Polyneuron's PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG NeuropathyPolyneuron is proud to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PN‑1007 (PPSGG) in the treatment of anti-MAG neuropathy, a disabling, chronic disorder of the peripheral nervous system. Orphan designation is granted to advance the development of… [read on]
-
General
Polyneuron receives approval to begin clinical study with PN-1007 in anti-MAG neuropathyWe are very proud to have received our first clinical trial application (CTA) approval in France, the Netherlands and the UK. We can now begin our planned phase I/IIa study of PN‑1007 for the treatment of anti-MAG neuropathy, a disabling, chronic disorder of… [read on]
-
General
Polyneuron announces appointment of chief medical officerWe are extremely pleased to welcome Dr Debra Barker to Polyneuron as our new chief medical officer. Dr Barker has a successful track record in drug development spanning over 25 years, involving many successful drug approvals. Press Release… [read on]
-
General
Polyneuron annouces appointment of new ChairmanPolyneuron announces the appointment of Ben Machielse as Chairman of the Board of Directors. Mr. Machielse supplements the strength of the Board following the appointments of David Mott of NEA and Graziano Seghezzi of Sofinnova Partners, who joined in March 2019 after the closing of… [read on]
-
General
EMA Orphan Drug Designation for PN-1007Polyneuron has obtained the orphan drug designation from the European Medicines Agency (EMA) for PN-1007 as a novel treatment for anti-MAG neuropathy. The EMA offers a range of incentives with the orphan designation, including free protocol assistance for SMEs, centralized authorization procedure, and extended market… [read on]
-
General
PN-1007 article published in PNASPolyneuron publishes top PN-1007 in vivo data in the renowned scientific journal “PNAS”. Article… [read on]